The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Response to crizotinib and cabozantinib in stage IV lung adenocarcinoma patients with mutations that cause MET exon 14 skipping.
 
Paul K. Paik
Honoraria - Celgene
Consulting or Advisory Role - Celgene; Threshold Pharmaceuticals
Research Funding - AstraZeneca; GlaxoSmithKline
 
Alexander E. Drilon
Honoraria - Exelixis; Genentech/Roche; Ignyta
Consulting or Advisory Role - Exelixis; Genentech/Roche
Speakers' Bureau - Ignyta
Research Funding - Foundation Medicine
Travel, Accommodations, Expenses - Exelixis; Genentech/Roche; Ignyta
 
Helena Alexandra Yu
No Relationships to Disclose
 
Lee M. Krug
Consulting or Advisory Role - Morphotek
Speakers' Bureau - Clovis Oncology; Merck Sharp & Dohme
Research Funding - Bristol-Myers Squibb (Inst); Genentech (Inst); Lilly (Inst); MedImmune (Inst)
 
Natasha Rekhtman
No Relationships to Disclose
 
Laetitia Borsu
No Relationships to Disclose
 
Michelle S. Ginsberg
No Relationships to Disclose
 
Michael F. Berger
Consulting or Advisory Role - Cancer Genetics
 
Marc Ladanyi
No Relationships to Disclose
 
Charles M. Rudin
Consulting or Advisory Role - Abbvie; AVEO; Boehringer Ingelheim; GlaxoSmithKline; Merck
Research Funding - Biomarin